Reem Karmali

Grants

Grants per year 2013 2015 2018 2019 2020 2025

• 6 Finished
• 18 Active

Grants per year

Search results

• Active

  Prot #TAK-007-2001: A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  Karmali, R.

  PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.

  6/10/22 → 6/10/25

  Project: Research project

• Prot #STU00215064: NU 20H09: Phase II, Single-arm, Open-label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-cell Therapy in Aggressive B-cell Non-Hodgkin's Lymphoma

  Karmali, R.

  BeiGene Switzerland GmbH

  12/21/21 → 12/21/24

  Project: Research project

• Prot #JCAR017-EAP-001: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel That Is Nonconforming for Commercial Release

  Karmali, R.

  DrugDev Inc., Juno Therapeutics, Inc.

  2/3/21 → 2/3/24

  Project: Research project

• Prot #KT-US-471-0119: A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)

  Karmali, R.

  Gilead Sciences, Inc., Kite Pharma, Inc.

  10/14/20 → 10/14/23

  Project: Research project

• Prot #RPM-CART-001: An Observational Study to Evaluate a Temperature Monitoring Device in Subjects Receiving CAR-T Therapy

  Karmali, R.

  Celgene Corporation

  9/28/20 → 9/28/23

  Project: Research project

• Prot #JCAR017-FOL-001: A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (NHL) (Transcend FL)

  Karmali, R.

  ICON Clinical Research, LLC, Celgene Corporation

  7/27/20 → 7/27/23

  Project: Research project

• Prot #JCAR017-BCM-003: A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TR

  Karmali, R.

  ICON Clinical Research, LLC, Celgene Corporation

  10/21/19 → 10/21/22

  Project: Research project

• Prot #NDS-NHL-001: A Global, Non-Interventional, Retrospective, Multi-Center Study To Generate Real-World Evidence Of Treatment Outcomes In Subjects With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  Karmali, R.

  Quintiles, Inc., Celgene Corporation

  9/18/19 → 9/18/24

  Project: Research project

• Prot #NEER-01: Network for Enigmatic Exceptional Responders to Cancer Treatment - The Cure is NEER

  Karmali, R.

  Takeda Pharmaceuticals U.S.A., Inc., Millennium Pharmaceuticals, Inc

  6/12/19 → 6/12/22

  Project: Research project

• Prot #X34001/NU 18H02: A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B cell Lymphoma (DLBCL)

  Karmali, R.

  GMA Research Corporation, Millennium Pharmaceuticals, Inc

  2/19/19 → 2/19/24

  Project: Research project

• Prot #GC-LTFU-001: Long-term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells

  Karmali, R.

  ICON Clinical Research, LLC, Celgene Corporation

  1/8/19 → 1/8/25

  Project: Research project

• Prot #KTE-C19-107: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

  Karmali, R.

  DrugDev Inc., Kite Pharma, Inc.

  10/12/18 → 10/12/23

  Project: Research project

• Prot #NU 17H08: Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination with R-CHOP in a Cohort of Patients with DLBCL/tFL/ high grade B-NHL

  Karmali, R.

  Bristol-Myers Squibb Company

  10/2/18 → 10/2/24

  Project: Research project

• Prot #JCAR017-BCM-002: An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM)

  Karmali, R.

  Celgene Corporation, Juno Therapeutics, Inc.

  4/17/18 → 4/17/24

  Project: Research project

• Prot #D8540C00001: A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/R

  Karmali, R.

  Covance Inc., MedImmune, LLC

  3/7/18 → 3/7/23

  Project: Research project

• Prot #VT3996-201: A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

  Karmali, R.

  CTI Clinical Trial and Consulting Services, Viracta Therapeutics, Inc.

  2/23/18 → 2/23/24

  Project: Research project

• Prot #PCI-32765MCL2003: NU 14H06: A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

  Karmali, R., Kaplan, J. B. & Pro, B.

  Janssen Scientific Affairs, LLC

  1/6/15 → 1/6/23

  Project: Research project

• Prot #C34001: An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

  Karmali, R. & Kaplan, J. B.

  Millennium Pharmaceuticals, Inc

  1/23/14 → 1/23/23

  Project: Research project

• Finished

  Prot #13676-01: A Phase 1 Multidose Study To Evaluate The Safety And Tolerability Of XmAb®13676 In Patients With Cd20-Expressing Hematologic Malignancies

  Karmali, R.

  Chiltern International, Inc., Xencor, Inc.

  9/1/17 → 9/1/20

  Project: Research project

• Impact of Cachexia on Clinical Outcomes in Aggressive Lymphomas

  Karmali, R.

  Lymphoma Research Foundation

  9/1/16 → 6/15/19

  Project: Research project

  • Cachexia 100%
  • Immunotherapy 64%
  • B-Cell Lymphoma 57%
  • Non-Hodgkin's Lymphoma 51%
  • Lymphoma 47%

• Prot #INCB 52793-101: A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

  Karmali, R. & Kaplan, J. B.

  Parexel, Incyte Corporation

  12/2/15 → 12/2/18

  Project: Research project

• Prot #INCB 54329-101: Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

  Karmali, R. & Kaplan, J. B.

  Covance Inc., Incyte Corporation

  9/11/15 → 9/11/18

  Project: Research project

• Prot #KCP-330-009: A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  Karmali, R. & Kaplan, J. B.

  Clinipace, Inc., Karyopharm Therapeutics Inc.

  12/23/14 → 12/23/20

  Project: Research project

• Prot #CC-122-DLBCL-001: A Phase 1B, Multi-Center, Open Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma

  Karmali, R. & Kaplan, J. B.

  Celgene Corporation

  9/17/13 → 9/17/19

  Project: Research project